EVOC4M
Research type
Research Study
Full title
Evaluation of Volatile Organic Compound signatures as a predictive and therapeutic response biomarker for Mepolizumab therapy in severe eosinophilic asthma
IRAS ID
286261
Contact name
Hitasha Rupani
Contact email
Sponsor organisation
University Hospital Southampton NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 6 days
Research summary
In patients with severe asthma identified to be “eosinophilic” on their blood tests, Mepolizumab (Nucala) successfully reduces the number of exacerbations they suffer from per year. As such, Mepolizumab has been licensed for use by severe asthma centres in the UK. However, around a third of patients, despite being eosinophilic on their blood tests, do not respond to Mepolizumab.
This study will recruit patients who are being prescribed Mepolizumab as part of their normal care. During their hospital visits, we will collect data and research samples to identify biomarkers that will discriminate between those that respond well to Mepolizumab (“responders”) and which do not (“non-responders”).
This will allow us to better understand how Mepolizumab works, why it doesn’t work in certain patients and better identify these patients from the start.REC name
London - Riverside Research Ethics Committee
REC reference
21/PR/0699
Date of REC Opinion
20 Jun 2021
REC opinion
Favourable Opinion